STOCK TITAN

Brainsway Ltd. - BWAY STOCK NEWS

Welcome to our dedicated page for Brainsway Ltd. news (Ticker: BWAY), a resource for investors and traders seeking the latest updates and insights on Brainsway Ltd. stock.

Overview of BrainsWay Ltd

BrainsWay Ltd (BWAY) is a pioneering global company specializing in advanced noninvasive neurostimulation treatments for brain disorders. With its headquarters located both in Jerusalem and the United States, the company has established a robust international presence and a growing portfolio of clinical evidence that supports its innovative approach to treating mental health conditions.

Innovative Technology and Core Business

At the heart of BrainsWay's offering is its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology. This breakthrough device delivers non-invasive magnetic pulses that stimulate neural circuits, offering a novel therapeutic alternative for patients who are inadequately served by traditional pharmacological treatments. The technology is designed to address a range of indications such as major depressive disorder, including anxious depression, obsessive-compulsive disorder, and smoking addiction. The Deep TMS system is engineered to be safe and convenient, requiring only brief daily sessions over a few weeks, thereby providing an accessible treatment option with minimal systemic or long-term side effects.

Clinical Validation and Industry Impact

BrainsWay's technology has been the subject of extensive research and multiple clinical trials, yielding pivotal data that supports its efficacy. The company’s approach not only addresses mental health conditions with rigorous clinical backing but also underscores the company’s commitment to advancing neurostimulation science. By integrating advanced coil designs and sophisticated software protocols, BrainsWay's Deep TMS offers targeted stimulation of specific brain regions. This precision in treatment delivery has established a new therapeutic paradigm in neuropsychiatry, especially for patients who have not responded optimally to medication.

Market Position and Revenue Model

BrainsWay operates at the intersection of medical device innovation and clinical neuroscience. The company generates revenue primarily through the sale and leasing of its Deep TMS systems to hospitals, mental health clinics, and research institutions worldwide. Its business model is reinforced by a series of strategic regulatory clearances, including several indications approved by the FDA, which not only validate the safety and efficacy of its technology but also serve as powerful market differentiators.

Global Reach and Expansion Strategy

With installations across multiple continents, including North America, Europe, and South America, BrainsWay has positioned itself as a key player in the global neurostimulation market. The company’s consistent focus on clinical excellence and technological innovation has bolstered its international footprint, making its life-changing therapy accessible to a diverse patient population. Its growth strategy emphasizes expanding its geographical presence and strengthening ties with healthcare providers, who are increasingly seeking alternatives to traditional treatment modalities.

Operational Excellence and Evidence-Based Approach

BrainsWay’s operational strategy is deeply rooted in rigorous scientific research and evidence-based medicine. Every aspect of its Deep TMS technology—from the design of its coils to the delivery protocols—has been optimized through clinical trials and post-market studies. The company’s transparent communication of clinical outcomes, patient benefits, and operational milestones reinforces its reputation for reliability and safety. BrainsWay provides clear, factual insights into the mechanics of its therapies, addressing both the technical and human elements of treatment, which is crucial in building trust with patients, practitioners, and investors alike.

Key Differentiators in the Competitive Landscape

In an industry marked by rapid innovation and evolving treatment paradigms, BrainsWay distinguishes itself through a blend of superior science, a strong clinical evidence base, and a commitment to patient-centric solutions. Unlike many conventional treatment methods, Deep TMS provides a non-invasive, well-tolerated, and efficient treatment alternative without the risks associated with invasive procedures. Furthermore, the company’s strategic focus on conditions with high unmet medical need sets it apart from competitors, cementing its role as an expert facilitator in advancing therapeutic outcomes for mental health disorders.

Operational and Strategic Highlights

  • Noninvasive Approach: The Deep TMS system offers a modern and patient-friendly alternative to invasive neurosurgical procedures, reducing both operational risk and recovery time.
  • Robust Clinical Evidence: The technology is supported by an extensive array of clinical studies that document significant improvements in symptomatology among patients with major depressive disorder, OCD, and smoking addiction.
  • Global Installations: With a growing number of installed systems around the world, BrainsWay has proven its ability to meet diverse market needs while contributing to improved patient outcomes on a global scale.
  • Revenue Generation: Through the leasing and sale of its Deep TMS systems to healthcare facilities and mental health centers, the company maintains a stable commercial base built on proven clinical benefits.

Understanding the Scientific and Clinical Rationale

The application of magnetic stimulation to the brain is based on sound neuroscience principles. Deep TMS targets specific neural networks associated with mood regulation and behavior, offering a precision-based treatment that can be finely tuned to individual patient needs. This meticulous approach to neurostimulation is a cornerstone of BrainsWay’s operational philosophy, ensuring that every treatment session is both clinically meaningful and scientifically substantiated.

Conclusion

BrainsWay Ltd stands as a beacon of innovation in the field of noninvasive neurostimulation, combining advanced technology with rigorous clinical science to offer effective treatment options for complex brain disorders. Its comprehensive approach—from state-of-the-art device design to extensive clinical validations—underscores the company’s authority and trustworthiness within the medical community. For anyone seeking a deep understanding of modern neuromodulation technologies and their applications in mental health treatments, BrainsWay represents a remarkable convergence of cutting-edge science, clinical precision, and a patient-focused operational model.

Rhea-AI Summary

BrainsWay (NASDAQ: BWAY) announced participation in two significant global medical conferences: the Clinical TMS Society Annual Meeting from June 10-12 and the Psych Congress Elevate from June 11-13, 2021. At the Clinical TMS Society event, BrainsWay will present seven posters showcasing the benefits of Deep TMS™ for mental health disorders, along with two showcase presentations. Dr. David Feifel will present at the Psych Congress discussing evidence for Deep TMS in OCD and smoking cessation. The company is focused on advancing innovative treatments for mental health issues.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
conferences
-
Rhea-AI Summary

BrainsWay Ltd. (NASDAQ: BWAY) announced a positive coverage policy from Health Care Service Corporation (HCSC) for its Deep TMS™ system, effective June 15, 2021, for treating obsessive-compulsive disorder (OCD). HCSC, covering approximately 17 million members, is a significant health insurer in the U.S. This coverage marks a milestone for BrainsWay, following other recent coverage announcements for OCD. The company aims to expand positive coverage from additional systems. OCD affects 2.3% of the U.S. population, resulting in a healthcare burden exceeding $7 billion annually.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
none
-
Rhea-AI Summary

BrainsWay Ltd. announced the publication of a draft Local Coverage Determination (LCD) by Palmetto GBA for its Deep TMS™ system, aimed at treating obsessive-compulsive disorder (OCD). This coverage proposal affects over 9 million Medicare patients across seven states. BrainsWay's management expressed optimism about improved access to treatment for patients unresponsive to standard therapies. The draft LCD aligns with clinical guidelines and follows a recent positive coverage decision from Centene. A formal meeting for public comments will take place before a final policy is issued.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
none
Rhea-AI Summary

BrainsWay Ltd. (NASDAQ: BWAY) announced that Centene Corporation will provide coverage for its Deep Transcranial Magnetic Stimulation (TMS) treatment for obsessive-compulsive disorder (OCD). This policy covers approximately 25 million members across the U.S. The decision follows a thorough review of clinical evidence supporting the safety and efficacy of Deep TMS. Centene’s coverage marks a significant development in expanding access to this treatment, particularly for patients resistant to standard therapies. The economic burden of OCD treatments exceeds $7 billion annually in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.55%
Tags
none
-
Rhea-AI Summary

BrainsWay reported Q1 2021 revenues of $6.1 million, marking a 47% year-over-year increase. The operating loss was $2.1 million, including a $2.0 million one-time stock compensation expense. The company ended the quarter with $58.5 million in cash after raising $45.2 million through a public offering. BrainsWay successfully launched its Deep TMS system for smoking cessation and received FDA clearance for its new depression treatment protocol. The installed base of Deep TMS systems grew by 19% to 652 units.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
-
Rhea-AI Summary

BrainsWay announced that President and CEO Christopher von Jako, Ph.D., will present at the Oppenheimer MedTech, Tools & Diagnostics Summit on May 26, 2021. The company will also conduct one-on-one investor meetings during the event. BrainsWay is a leader in advanced noninvasive treatments for brain disorders, utilizing its proprietary Deep TMS technology. The FDA has cleared three indications for its treatments: major depressive disorder, obsessive-compulsive disorder, and smoking addiction. Additional clinical trials are ongoing to expand the reach of Deep TMS.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
conferences
Rhea-AI Summary

BrainsWay Ltd. (NASDAQ: BWAY) will report its first quarter 2021 financial results on May 20, 2021, before U.S. markets open. A conference call and webcast will follow at 8:30 AM ET to discuss these results and provide operational updates. BrainsWay is known for its advanced neurostimulation treatments, holding three FDA-cleared indications for mental health disorders including major depressive disorder. The company aims to expand awareness and access to its Deep Transcranial Magnetic Stimulation technology worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
conferences earnings
-
Rhea-AI Summary

BrainsWay Ltd. (NASDAQ: BWAY) announced the appointment of R. Scott Areglado as Senior Vice President and Chief Financial Officer, effective immediately. This leadership change aims to strengthen financial operations as the company expands its commercial efforts in noninvasive neurostimulation treatments for mental health disorders. Areglado brings over 25 years of experience in finance within the medical technology sector, previously serving as CFO at iCAD, Inc. His leadership is expected to drive long-term growth and value for stakeholders amid increasing mental health awareness.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
management
-
Rhea-AI Summary

BrainsWay Ltd (NASDAQ: BWAY) has announced the distribution of its first 10 Deep Transcranial Magnetic Stimulation (Deep TMS) devices aimed at aiding short-term smoking cessation. This FDA-cleared treatment employs electromagnetic pulses to stimulate brain areas linked to addiction. A 2019 study of 262 smokers showed significant improvements in quit rates and reduction in cravings. The treatment is now accessible in multiple states, including clinics in Florida, New York, and Texas. BrainsWay aims to provide an effective noninvasive option for those struggling with tobacco addiction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
none
Rhea-AI Summary

BrainsWay Ltd. announced FDA 501(k) clearance for its Theta Burst three-minute protocol using the Deep TMS system for treating major depressive disorder (MDD). This shorter treatment option aims to enhance patient access to care and improve flexibility for providers and patients. Clinical data from 146 subjects indicated significant reductions in depression scores for both the standard and three-minute protocols. The new protocol will be available immediately on all existing BrainsWay systems.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.25%
Tags
none

FAQ

What is the current stock price of Brainsway Ltd. (BWAY)?

The current stock price of Brainsway Ltd. (BWAY) is $9.19 as of April 1, 2025.

What is the market cap of Brainsway Ltd. (BWAY)?

The market cap of Brainsway Ltd. (BWAY) is approximately 173.0M.

What is the core technology behind BrainsWay Ltd?

BrainsWay utilizes its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology, a noninvasive method that stimulates neural circuits to alleviate brain disorders such as major depressive disorder, OCD, and smoking addiction.

How does BrainsWay generate its revenue?

The company earns revenue primarily through the sale and leasing of its Deep TMS systems to hospital networks, clinical centers, and research facilities worldwide.

Which mental health conditions does BrainsWay target with its technology?

BrainsWay’s Deep TMS technology is indicated for major depressive disorder (including anxious depression), obsessive-compulsive disorder, and smoking addiction, with ongoing clinical trials exploring additional psychiatric and neurological applications.

What makes Deep TMS different from other brain stimulation therapies?

Unlike invasive procedures, Deep TMS is a noninvasive treatment that is both safe and convenient, offering targeted stimulation of neural networks with minimal side effects, which makes it a compelling alternative for patients unresponsive to traditional therapies.

How is BrainsWay positioned within the neurostimulation market?

BrainsWay is recognized for its robust clinical evidence, innovative technology, and global reach. Its regulatory clearances and focus on high unmet medical needs distinguish it in a competitive field of neuromodulation treatment providers.

What evidence supports the efficacy of BrainsWay's technology?

The company’s numerous clinical trials and pivotal studies have demonstrated significant improvements in patient symptomatology for various conditions, reinforcing the clinical efficacy and safety profile of the Deep TMS system.
Brainsway Ltd.

Nasdaq:BWAY

BWAY Rankings

BWAY Stock Data

173.03M
15.56M
6.42%
32.12%
0.29%
Medical Devices
Healthcare
Link
Israel
Jerusalem